6-145735264-C-G

Variant summary

Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting

The NM_005670.4(EPM2A):ā€‹c.235G>Cā€‹(p.Gly79Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000646 in 1,517,924 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā˜…ā˜…).

Frequency

Genomes: š‘“ 0.00036 ( 0 hom., cov: 32)
Exomes š‘“: 0.000031 ( 0 hom. )

Consequence

EPM2A
NM_005670.4 missense

Scores

2
6
10

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:5B:1

Conservation

PhyloP100: 0.0390
Variant links:
Genes affected
EPM2A (HGNC:3413): (EPM2A glucan phosphatase, laforin) This gene encodes a dual-specificity phosphatase and may be involved in the regulation of glycogen metabolism. The protein acts on complex carbohydrates to prevent glycogen hyperphosphorylation, thus avoiding the formation of insoluble aggregates. Loss-of-function mutations in this gene have been associated with Lafora disease, a rare, adult-onset recessive neurodegenerative disease, which results in myoclonus epilepsy and usually results in death several years after the onset of symptoms. The disease is characterized by the accumulation of insoluble particles called Lafora bodies, which are derived from glycogen. [provided by RefSeq, Jan 2018]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -3 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.05141419).
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.000363 (55/151558) while in subpopulation AFR AF= 0.00123 (51/41504). AF 95% confidence interval is 0.000959. There are 0 homozygotes in gnomad4. There are 18 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
EPM2ANM_005670.4 linkuse as main transcriptc.235G>C p.Gly79Arg missense_variant 1/4 ENST00000367519.9 NP_005661.1
EPM2A-DTNR_038246.1 linkuse as main transcriptn.52+344C>G intron_variant, non_coding_transcript_variant

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
EPM2AENST00000367519.9 linkuse as main transcriptc.235G>C p.Gly79Arg missense_variant 1/41 NM_005670.4 ENSP00000356489 P1O95278-1

Frequencies

GnomAD3 genomes
AF:
0.000363
AC:
55
AN:
151450
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00123
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000131
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.000961
GnomAD3 exomes
AF:
0.0000513
AC:
7
AN:
136456
Hom.:
0
AF XY:
0.0000133
AC XY:
1
AN XY:
74990
show subpopulations
Gnomad AFR exome
AF:
0.00122
Gnomad AMR exome
AF:
0.0000440
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000315
AC:
43
AN:
1366366
Hom.:
0
Cov.:
30
AF XY:
0.0000222
AC XY:
15
AN XY:
675480
show subpopulations
Gnomad4 AFR exome
AF:
0.00130
Gnomad4 AMR exome
AF:
0.0000294
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00
Gnomad4 OTH exome
AF:
0.0000896
GnomAD4 genome
AF:
0.000363
AC:
55
AN:
151558
Hom.:
0
Cov.:
32
AF XY:
0.000243
AC XY:
18
AN XY:
74078
show subpopulations
Gnomad4 AFR
AF:
0.00123
Gnomad4 AMR
AF:
0.000131
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.000951
Alfa
AF:
0.000229
Hom.:
0
Bravo
AF:
0.000563
ESP6500AA
AF:
0.000469
AC:
2
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.0000718
AC:
8

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:5Benign:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingGeneDxApr 15, 2024In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Uncertain significance, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Nov 11, 2014- -
Lafora disease Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsOct 31, 2018- -
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsAug 01, 2018The p.G79R variant (also known as c.235G>C), located in coding exon 1 of the EPM2A gene, results from a G to C substitution at nucleotide position 235. The glycine at codon 79 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is well conserved on limited sequence alignment. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. -
Progressive myoclonic epilepsy Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpOct 18, 2022This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 79 of the EPM2A protein (p.Gly79Arg). This variant is present in population databases (rs374826256, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with EPM2A-related conditions. ClinVar contains an entry for this variant (Variation ID: 193326). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
EPM2A-related disorder Benign:1
Likely benign, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesApr 08, 2024This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
-0.084
T
BayesDel_noAF
Uncertain
0.090
CADD
Benign
19
DANN
Uncertain
0.98
DEOGEN2
Uncertain
0.42
T;.;.;.
Eigen
Benign
-0.24
Eigen_PC
Benign
-0.23
FATHMM_MKL
Uncertain
0.79
D
LIST_S2
Benign
0.77
T;T;.;T
M_CAP
Pathogenic
0.89
D
MetaRNN
Benign
0.051
T;T;T;T
MetaSVM
Uncertain
0.16
D
MutationAssessor
Benign
1.7
L;L;L;L
MutationTaster
Benign
0.65
N
PrimateAI
Pathogenic
0.81
D
PROVEAN
Benign
-0.74
N;.;.;.
REVEL
Uncertain
0.55
Sift
Benign
0.36
T;.;.;.
Sift4G
Benign
0.27
T;T;.;.
Polyphen
0.26
B;B;B;.
Vest4
0.16
MVP
0.96
MPC
0.37
ClinPred
0.12
T
GERP RS
2.2
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
gMVP
0.49

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs374826256; hg19: chr6-146056400; API